We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Cell Therapeutics Announces Resignation of Chief Medical Officer
News

Cell Therapeutics Announces Resignation of Chief Medical Officer

Cell Therapeutics Announces Resignation of Chief Medical Officer
News

Cell Therapeutics Announces Resignation of Chief Medical Officer

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Cell Therapeutics Announces Resignation of Chief Medical Officer"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Cell Therapeutics, Inc. has announced the resignation of Steven E. Benner, M.D., M.H.S., Senior Vice President, Chief Medical Officer and Chief Compliance Officer for personal reasons.

Nancy Boman, M.D., Ph.D., Senior Vice President, Clinical Development and Regulatory Affairs, is expected to assume interim responsibility for the oversight of CTI's ongoing and planned clinical trials of compounds for the treatment of blood cancers.

CTI has engaged a search firm to assist in an external search for a new Chief Medical Officer and will appoint a new Chief Compliance Officer.

Immediately prior to his resignation, based on public records, Dr. Benner beneficially owned 396,705 shares of CTI's common stock.

"Steve has established a strong leadership team in the clinical organization that is focused on advancing our two ongoing late-stage clinical programs for pacritinib and PIXUVRI® (pixantrone). We acknowledge and thank Steve for his significant contributions to these programs and wish him the very best in his future endeavors," said James A. Bianco, M.D., President and CEO of CTI.

Dr. Bianco added, "As we move toward initiating the second planned Phase 3 clinical trial evaluating pacritinib, our JAK2/FLT3 inhibitor for the treatment of patients with myelofibrosis later this year, we are confident that the clinical and regulatory team we have in place will continue to execute and our development plans will remain on track."

Advertisement